Delivery Order SPE2DB22D2108-SPE2DB25FU5EE
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order contract on August 4, 2025, by the Defense Logistics Agency for the supply of ELIQUIS 5 mg tablets (60-count units) under a firm fixed price arrangement with a ceiling value of $28,274.15. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 5, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $3,826.92 by the Defense Logistics Agency for the supply of Eliquis 5 mg tablets (60-count packaging). The award was issued on July 30, 2025, with an ultimate completion date of July 31, 2025, and is structured as a firm fixed price contract with no set-aside designation. The contract represents a competitive award to AmerisourceBergen's Corporate Office, headquartered in Conshohocken, Pennsylvania, where the performance...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a $10,118.76 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical to provide ELIQUIS 5 MG TABLET 60S. The delivery order is part of an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that serves as the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) on August 13, 2025, for Eliquis 5 mg tablets in a 60-count package. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $10,815.81 and is set to be completed by August 14, 2025. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $19,111.33 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units). This contract, executed on July 29, 2025, with an ultimate completion date of July 30, 2025, utilizes firm fixed-price pricing and was competitively awarded without any set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,436.59 firm fixed price delivery order by the Defense Logistics Agency (DLA) Troop Support Medical to provide ELIQUIS 5 MG TABLET 60S. The delivery order has a completion date of February 22, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 and running through December 31, 2025, which serves as the primary...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical to provide ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a potential value of $8,531.24. This order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of up to $999,999,999.00 and a performance period through...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a firm fixed-price delivery order valued at $95,223.63 by the Defense Logistics Agency (DLA) for the supply of Eliquis 5 mg tablets (60-count units). The contract, awarded August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-competitive, open-market award. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $39,230.84 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical to provide ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a completion date of May 11, 2022. This delivery order is issued under Amerisourcebergen Drug Corp's single award indefinite delivery contract (IDC) with DLA, which has a potential value of $999,999,999.00 and a performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,827.12 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract. The delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-competitive, competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5EEDelivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for ELIQUIS 5 mg tablets (60 count) with a ceiling value of $28,889.03 and a firm fixed price structure. The award was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract contains no set-aside designation and was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive pharmaceutical support vehicle enables the company to supply a broad range of medications and medical supplies to support military healthcare programs globally. The DLA established this prime vendor relationship as part of its strategy to ensure reliable, competitively-awarded pharmaceutical procurement for the Defense Health Agency and other federal healthcare systems, with the agency planning subsequent regional contracts under its Pharmaceutical Prime Vendor Global Program Generation V initiative.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.9k | 7/22/25 |